Northcape Wealth Management LLC Buys Shares of 8,724 Stryker Corporation $SYK

Northcape Wealth Management LLC bought a new position in shares of Stryker Corporation (NYSE:SYK) in the second quarter, HoldingsChannel reports. The firm bought 8,724 shares of the medical technology company’s stock, valued at approximately $2,747,000.

Several other institutional investors and hedge funds also recently modified their holdings of SYK. Edmond DE Rothschild Holding S.A. acquired a new stake in shares of Stryker in the second quarter valued at approximately $44,000. Strathmore Capital Advisors Inc. acquired a new position in shares of Stryker during the 2nd quarter worth approximately $397,000. Madison Asset Management LLC purchased a new stake in Stryker in the 2nd quarter valued at approximately $3,221,000. Csenge Advisory Group acquired a new stake in Stryker during the 2nd quarter valued at $843,000. Finally, AssuredPartners Investment Advisors LLC purchased a new position in Stryker during the second quarter worth $298,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Up 2.7%

SYK opened at $340.20 on Thursday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $396.86. The business has a 50-day moving average of $326.19 and a two-hundred day moving average of $332.95. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The stock has a market capitalization of $130.49 billion, a price-to-earnings ratio of 35.25, a price-to-earnings-growth ratio of 2.11 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping the consensus estimate of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. During the same period in the prior year, the firm posted $3.13 EPS. The company’s revenue was up 9.4% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. Stryker’s payout ratio is currently 36.48%.

Insider Transactions at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the business’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the completion of the sale, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. The trade was a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Robert S. Fletcher sold 4,544 shares of the company’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total value of $1,394,417.28. Following the sale, the vice president owned 10,582 shares of the company’s stock, valued at $3,247,298.34. This represents a 30.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 315,370 shares of company stock worth $98,463,501 in the last ninety days. Insiders own 4.60% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on SYK shares. Needham & Company LLC cut their price target on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a report on Friday, May 1st. Citizens Jmp dropped their price objective on Stryker from $440.00 to $400.00 and set a “market outperform” rating for the company in a research report on Monday, August 3rd. Raymond James Financial set a $370.00 target price on shares of Stryker in a research note on Friday, July 31st. Piper Sandler decreased their price target on shares of Stryker from $420.00 to $390.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Wall Street Zen upgraded shares of Stryker from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.